Due to their frequent alterations, targeting the receptor and protein kinase components of the PI3K and RAS-MAPK signalling pathways have been attractive therapeutic approaches for BC, reflected by an increasing array of targeted agents under active development and clinical testing[22,23][Figure 1B]. This evidence concerns the gene PIK3CD and breast cancer.